Background {#section1-1076029619849103}
==========

Venous thromboembolism (VTE) is considered a serious and potentially life-threatening medical condition.^[@bibr1-1076029619849103]^ The annual incidence of VTE (deep venous thrombosis \[DVT\] and pulmonary embolism \[PE\]), in Europeans as an example, is estimated to be 104 to 183 per 100 000 person-years.^[@bibr2-1076029619849103]^ Incidence rates of DVT (without PE) and PE (without DVT) are 45 to 117 and 29 to 78 per 100 000 person-years, respectively.^[@bibr3-1076029619849103][@bibr4-1076029619849103][@bibr5-1076029619849103]--[@bibr6-1076029619849103]^ These rates are higher among the African American population and lower among the Native American population, Asian, and Asian American populations.^[@bibr2-1076029619849103]^

Risk factors for VTE include advanced age, overweight, hospitalization, immobility, especially after total hip replacement (THR) and total knee replacement (TKR) surgeries, active cancer, trauma, fractures, and superficial vein thrombosis.^[@bibr7-1076029619849103]^

Before 2010, the mainstay pharmacologic prophylaxis and treatment of VTE were warfarin, heparin, low-molecular-weight heparin (LMWH), and fondaparinux.^[@bibr8-1076029619849103]^ Since the introduction of the first direct oral anticoagulant (DOAC), that is, dabigatran, in 2010, the anticoagulation landscape has started to change. Since then, several other DOACs have been approved, including rivaroxaban, apixaban, edoxaban, and betrixaban. Direct oral anticoagulants offer potential advantages compared to warfarin including fixed dosing, lack of food and drug interactions, minimal need for monitoring, and superior safety profile. Direct oral anticoagulants, however, are associated with an increased risk of gastrointestinal adverse drug reactions (dabigatran and rivaroxaban), lack of an easily monitored surrogate marker, and higher cost.^[@bibr9-1076029619849103]^

Numerous studies and systematic reviews have compared DOACs with warfarin in terms of their cost-effectiveness and cost benefit.^[@bibr10-1076029619849103][@bibr11-1076029619849103][@bibr12-1076029619849103][@bibr13-1076029619849103][@bibr14-1076029619849103][@bibr15-1076029619849103][@bibr16-1076029619849103][@bibr17-1076029619849103]--[@bibr18-1076029619849103]^ Apart from 1 report that was conducted on studies published till 2014,^[@bibr19-1076029619849103]^ there have been no updated systematic reviews comparing among DOACs (either directly or indirectly) in the prevention and treatment of VTE. In this systematic review, we aim to explore studies comparing the cost-effectiveness of DOACs in the treatment and prevention of VTE.

The objective of this systematic review is to summarize and compare the main cost-effectiveness outcomes in studies comparing DOAC agents in the prevention and treatment of VTE. This will answer the question about which of the DOACs is the most cost-effective in the prevention and treatment of VTE.

Methods {#section2-1076029619849103}
=======

The Literature Search {#section3-1076029619849103}
---------------------

A systematic search of the literature was conducted via the following databases: PubMed, Embase, and EconLit. The search strategy followed the PICO format. As an example, within the PubMed database, the population was: venous thromboembolism, VTE, deep venous thrombosis, DVT, pulmonary embolism, PE, atrial fibrillation, AF, stroke; the intervention/comparator was: anticoagulants, rivaroxaban, dabigatran, apixaban, edoxaban, direct oral anticoagulant, novel oral anticoagulant, DOAC, NOAC; the outcome was cost-effectiveness, cost-benefit, cost analysis, economics, cost of illness, cost savings, cost control. A similar search strategy was used with the other search databases. Key words were customized to database-specific indexing terms, for example, the use of MeSH terms. As appropriate, the terms and their alternatives were combined with Boolean connectors (AND/OR/NOT). In addition to the electronic search, we performed a manual search of bibliographies and references of identified articles and cost-related specific issues in journals. The gray literature search also included preliminary progress and advanced reports, theses, conference proceeding, technical reports, and guidelines, in addition to searching indexing terms via the Google search engine. A search protocol of the systematic review was developed and registered in PROSPERO (ID\# CRD42018098705).

Study Types {#section4-1076029619849103}
-----------

Any cost-effectiveness study comparing DOACs in the treatment and/or prevention of VTE.

Participants {#section5-1076029619849103}
------------

Patients treated with DOACs for the treatment and/or prevention of VTE.

Eligibility Criteria {#section6-1076029619849103}
--------------------

Studies were considered eligible for this review if they were pharmacoeconomic studies comparing more than 1 DOAC in adults (\>18 years old) for the prevention or treatment of VTE, including DVT and/or PE. We included only comparative studies in the English language, of human species, and in journal articles with full-text availability from January 1, 2010 (the year of the first approved DOAC\]dabigatran\[) to February, 2018 (the date this review was conducted). Exclusion criteria include reviews, noncomparative studies, and studies with a single DOAC alone as a comparator or against warfarin. The selection of articles was conducted via 2 independent reviewers by the initial screening of titles/abstracts of articles, before a follow-up screening of the full text. When disagreements occurred, articles were discussed with a third reviewer until consensus.

Outcome Measures {#section7-1076029619849103}
----------------

The outcome measure of interest is the observed trends in relation to the comparative economic outcomes of the DOAC agents, dabigatran, rivaroxaban, apixaban, edoxaban, and betrixaban, including total cost, cost avoidance, and the incremental cost-effectiveness ratio (ICER). Also a comparative outcome of interest is when a DOAC is both more effective and less costly than another (ie, dominant DOAC), or the converse (ie, dominated DOAC), in which case the ICER becomes meaningless.

Data Extraction and Synthesis {#section8-1076029619849103}
-----------------------------

A data extraction tool was developed and pilot tested using a sample of the eligible studies (n = 3). The extracted data includes the DOACs compared, country, disease states, eligibility criteria, primary and secondary outcomes (efficacy and pharmacoeconomic), funding, the comparative model used, type of cost-effectiveness analysis, uncertainty tests, and summary of findings. If any of the information was missing, the corresponding author of a particular article was contacted. Two reviewers independently extracted data from included articles, ensuring data reliability and trustworthiness. A consensus was reached whenever differences occurred.

Assessment of Quality of Studies {#section9-1076029619849103}
--------------------------------

As with the study inclusion and data extraction, the quality of articles was assessed by 2 independent reviewers who critically appraised the included articles to assess the risk of bias and methodological quality. For the purpose, the Quality of Health Economic Studies (QHES) tool^[@bibr20-1076029619849103]^ was utilized. The QHES includes 16 questions, and each question has a different score ranging from "0" to "9," with the total of all questions scores adding to 100 points. The interpretation of a QHES score was as per 1 of 4 categories of quality, that is, good, fair, poor, and extremely poor, associated with the scores 75 to 100, 50 to 74, 25 to 49, and 0-24, respectively.^[@bibr21-1076029619849103][@bibr22-1076029619849103][@bibr23-1076029619849103]--[@bibr24-1076029619849103]^ A third independent reviewer would contribute whenever a disagreement occurs.

Only articles with fair or good methodological quality were included in this review.^[@bibr22-1076029619849103]^ The systematic review followed the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guideline, including a 27-item checklist of essential items to be reported in a systematic review.^[@bibr25-1076029619849103]^

Results {#section10-1076029619849103}
=======

Study Selection {#section11-1076029619849103}
---------------

Of a total of 704 retrieved articles, 7 articles met the inclusion/exclusion criteria. Search results are illustrated in [Figure 1](#fig1-1076029619849103){ref-type="fig"}.

![Flow diagram.^[@bibr10-1076029619849103]^](10.1177_1076029619849103-fig1){#fig1-1076029619849103}

Characteristics of the Included Articles {#section12-1076029619849103}
----------------------------------------

All studies in this review included dabigatran and rivaroxaban as part of the DOACs compared.^[@bibr26-1076029619849103][@bibr27-1076029619849103][@bibr28-1076029619849103][@bibr29-1076029619849103][@bibr30-1076029619849103][@bibr31-1076029619849103]--[@bibr32-1076029619849103]^ Apixaban was included in 6 studies and edoxaban was included in 2 studies only. Furthermore, because of how recently approved it is, betrixaban was not included in any of the studies. The majority of the articles used Markov modeling that follows cohorts of patients over follow-up periods of 3, 6, and 12 months as well as the lifetime of patients, with 3- or 6-month transitional model cycles. The only exception was the study by Amin et al, where a non-Markov simulation was used to follow-up patients over 1 year from having recurrent VTE.

In general, all studies used pivotal trials versus warfarin as primary sources of clinical inputs for dabigatran (RE-COVER, RE-COVER II, and RE-MED),^[@bibr33-1076029619849103][@bibr34-1076029619849103]--[@bibr35-1076029619849103]^ rivaroxaban (EINSTEIN, EINSTEIN-DVT, and EINSTEIN-PE),^[@bibr36-1076029619849103][@bibr37-1076029619849103]--[@bibr38-1076029619849103]^ apixaban (AMPLIFY and AMPLIFY-EXT)^[@bibr39-1076029619849103],[@bibr40-1076029619849103]^ and edoxaban (Hokusai-VTE).^[@bibr41-1076029619849103]^ The modeled clinical events in included cost-effectiveness studies were therefore fairly consistent. Clinical efficacy and safety events included recurrent VTE and VTE-related death, minor bleeding, major bleeding, and clinically relevant non-major bleeding (CRNMB). Other events were chronic thromboembolic pulmonary hypertension, post thromboembolic syndrome, and intracranial bleed. These clinical events were evaluated over patient lifetime,^[@bibr26-1076029619849103],[@bibr27-1076029619849103],[@bibr29-1076029619849103],[@bibr32-1076029619849103]^ except for Amin et al where the events were evaluated on annual basis.^[@bibr28-1076029619849103],[@bibr30-1076029619849103],[@bibr31-1076029619849103]^

Among the 7 included studies, 3 were conducted in the United States,^[@bibr28-1076029619849103],[@bibr30-1076029619849103],[@bibr31-1076029619849103]^ 2 in the United Kingdom,^[@bibr26-1076029619849103],[@bibr32-1076029619849103]^ and 2 in Canada.^[@bibr27-1076029619849103],[@bibr29-1076029619849103]^ The most common measure for the cost-effectiveness evaluation was cost/ICAR (QALY), and it was used in 4 studies.^[@bibr26-1076029619849103],[@bibr27-1076029619849103],[@bibr29-1076029619849103],[@bibr32-1076029619849103]^ Annual total medical cost avoidance was used in 2 studies^[@bibr28-1076029619849103],[@bibr30-1076029619849103]^ and annual total medical cost differences in 1 study.^[@bibr31-1076029619849103]^ In regard to funding, 6 studies were funded by drug sponsors,^[@bibr26-1076029619849103][@bibr27-1076029619849103]--[@bibr28-1076029619849103],[@bibr30-1076029619849103][@bibr31-1076029619849103]--[@bibr32-1076029619849103]^ while no funding was received by Al Saleh et al. [Table 1](#table1-1076029619849103){ref-type="table"} summarizes the general characteristics of the included articles.

###### 

General Characteristics of the Included Articles.

![](10.1177_1076029619849103-table1)

  Author                                       Comparators                                    Setting          Year   Analysis Type                           Population
  -------------------------------------------- ---------------------------------------------- ---------------- ------ --------------------------------------- ------------------------------------------------
  Al Saleh et al^[@bibr29-1076029619849103]^   Dabigatran, Rivaroxaban, Apixaban, Warfarin    Canada           2017   ICER (Cost/QALY)                        Treatment of DVT and PE in outpatient settings
  Amin et al^[@bibr30-1076029619849103]^       Dabigatran, Rivaroxaban, Apixaban (2.5-5 mg)   United States    2014   Annual total medical cost avoidance     Extended treatment of VTE
  Amin et.al^[@bibr31-1076029619849103]^       Dabigatran, Rivaroxaban, Apixaban, Edoxaban    United States    2014   Annual total medical cost differences   Treatment of VTE
  Amin et al^[@bibr28-1076029619849103]^       Dabigatran, Rivaroxaban, Apixaban, Edoxaban    United States    2015   Annual total medical cost avoidances    Treatment of VTE
  Jurgin et al^[@bibr26-1076029619849103]^     Dabigatran, Rivaroxaban                        United Kingdom   2015   ICER (Cost/QALY)                        Treatment and extended treatment of VTE
  Lanitis et al^[@bibr32-1076029619849103]^    Dabigatran, Rivaroxaban, Apixaban, Warfarin    United Kingdom   2016   ICER (Cost/QALY)                        Initial treatment of VTE
  Quon et al^[@bibr27-1076029619849103]^       Dabigatran, Rivaroxaban, Apixaban, Warfarin    Canada           2016   ICER (Cost/QALY)                        Treatment and prevention of recurrence of VTE

Abbreviations: DVT, deep venous thrombosis; ICER, incremental cost-effectiveness ratio; PE, pulmonary embolism; QALY, quality-adjusted life-years; VTE, venous thromboembolism.

Efficacy End Point Results {#section13-1076029619849103}
--------------------------

Different measures were used in different studies to assess the efficacy of each DOAC. Three studies reported differences in absolute clinical event rates versus placebo, control, and warfarin.^[@bibr28-1076029619849103],[@bibr30-1076029619849103],[@bibr31-1076029619849103]^ Two studies reported results in terms of a number of events among a cohort of 10 000 patients.^[@bibr27-1076029619849103],[@bibr32-1076029619849103]^ One study reported fatality rates and one study reported relative risk (RR) of recurrent VTE.^[@bibr26-1076029619849103],[@bibr29-1076029619849103]^ Most articles conducted univariate (1-way) sensitivity analysis to determine the impact of every single parameter used in the analysis model on the total medical cost estimated through the model. Amin et al concluded in all of their 3 studies that variations in both VTE and major bleeding had the highest impact on medical cost differences in terms of total medical cost differences and avoidance between DOACs, standard therapy, and placebo.^[@bibr28-1076029619849103],[@bibr30-1076029619849103],[@bibr31-1076029619849103]^ Al Saleh et al reported that fatality rates in the short run and pharmaceutical care were the highest determinants to uncertainty in the conducted analysis.^[@bibr29-1076029619849103]^ Quon et al concluded that both major and CRNMB events were the main drivers for apixaban being the cost-effective choice among other DOACs.^[@bibr27-1076029619849103]^ Lanitis et al reported that apixaban

would not be considered a dominant choice when the differential price between other DOACs and apixaban increased and when the relative risk of recurrent VTE is reduced for rivaroxaban versus apixaban from a baseline 1.08 to 0.69.^[@bibr32-1076029619849103]^ [Table 2](#table2-1076029619849103){ref-type="table"} summarizes the efficacy end points for each DOAC in terms of recurrent VTE.

###### 

Recurrent VTE Efficacy End Point Results.

![](10.1177_1076029619849103-table2)

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author                                       Measure Used                                         Clinical Events Results
  -------------------------------------------- ---------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Al Saleh et al^[@bibr29-1076029619849103]^   Fatality rates                                       Recurrent DVT/PE = 2.55%, 1.88%, 1.78%, and 2.14% for dabigatran + LMWH, rivaroxaban, apixaban, and VKA + LMWH, respectively

  Amin et al^[@bibr30-1076029619849103]^       Differences in absolute clinical event rates         Recurrent VTE = −5.15% (−5.48% to −4.19%)^a^, −5.74% (−6.43% to −4.31%)^a^, −7.14% (−7.84% to −5.90%)^a^, −7.08% (−7.84% to −5.81%)^a^ for dabigatran, rivaroxaban, apixaban 2.5 mg, and apixaban 5 mg, respectively (vs placebo)

  Amin et al^[@bibr31-1076029619849103]^       Differences in absolute clinical event rates         Recurrent VTE/VTE related death = 0.20% (−0.52% to 1.22%)^a^, −0.23% (−0.78% to 0.44%)^a^, −0.43% (−1.08% to 0.49%), ^a^ and −0.34% (−0.78% to 0.27%)^a^ for dabigatran, rivaroxaban, apixaban 2.5 mg and apixaban 5 mg, respectively (vs control)

  Amin et al^[@bibr28-1076029619849103]^       Differences in absolute clinical event rates         Recurrent VTE among patients with VTE = 1.02% (−2.69 to 6.35%)^a^, −1.23% (−3.81% to 2.13%)^a^, −1.80% (−4.48% to 2.02%)^a^, and −2.02% (−4.48% to 1.57%)^a^ for dabigatran, rivaroxaban, apixaban and edoxaban, respectively (vs warfarin)

  Jurgin et al^[@bibr26-1076029619849103]^     Relative risk (RR)                                   Recurrent VTE (3, 6, 12 months) = RR for rivaroxaban vs dabigatran = 0.83 (0.46 to 1.49)^a^\
                                                                                                    Recurrent VTE (6 months) = RR for rivaroxaban vs dabigatran = 0.90 (0.53, 1.52)^a^

  Lanitis et al^[@bibr32-1076029619849103]^    Number of events among (cohort of 10 000 patients)   Recurrent VTE/VTE-related death (6-month treatment over patient lifetime) = 604, 601, 600, and 602 for dabigatran/LMWH, rivaroxaban, apixaban, and VKA/LMWH, respectively

  Quon et al^[@bibr27-1076029619849103]^       Number of events (cohort of 10 000 patients)         Recurrent VTE events = 520, 512, 521, and 607 for dabigatran, rivaroxaban, apixaban, and enoxaparin/VKA, respectively, for up to 18 months treatment over patient life time with DOACs or 6 months of enoxaparin/VKA
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: DVT, deep venous thrombosis; LMWH, low-molecular-weight heparin; PE, pulmonary embolism; RR, relative risk; VKA, vitamin K antagonist; VTE, venous thromboembolism.

^a^95% Confidence interval (CI).

Cost-Effectiveness Results {#section14-1076029619849103}
--------------------------

Measures used to assess the cost-effectiveness of DOACs were not the same among the different studies. The majority of studies (n = 4) mostly used the cost/QALY measure, including the total costs calculations.^[@bibr26-1076029619849103],[@bibr27-1076029619849103],[@bibr29-1076029619849103],[@bibr32-1076029619849103]^ Jurgin et al reported that for 6-month therapy with dabigatran compared to 3-, 6-, and 12-month treatment with rivaroxaban for VTE treatment and extended anticoagulation and index DVT and PE treatment among a cohort of 10 000 patients, dabigatran is dominant over rivaroxaban, having lower cost and higher QALY, in all these settings. A similar trend was observed in their study evaluating the VTE treatment and extended anticoagulation indication, and for index DVT and PE treatment in 6-month therapy among a cohort of 10 000 patients for both dabigatran and rivaroxaban, where dabigatran also dominates rivaroxaban in all these settings. In a 6-month evaluation of VTE treatment over a patient's lifetime, Lanitis et al reported apixaban to be dominant over both rivaroxaban and LMWH/dabigatran, with total costs of £4696, £4731, and £4792 with each, respectively. Apixaban did not dominate LMWH/warfarin, with apixaban costing £2520 over the latter per QALY. In overall, the per-patient treatment, administration, and monitoring costs were lower with apixaban by £11 and £45 compared to rivaroxaban and LMWH/dabigatran, respectively. In the study by Quon et al, the total lifetime costs per patient with up to 18 months of DOACs or 6 months of enoxaparin/warfarin were reported. Apixaban had lower costs and longer survival or higher QALYs compared to enoxaparin/warfarin, rivaroxaban, and dabigatran. Al Saleh et al reported the comparative cost/QALY among the therapies LMWH/VKA, LMWH/dabigatran, rivaroxaban, and apixaban. Apixaban dominated other DOACs with an ICER of US\$84.08 relative to LMWH/VKA. Furthermore, at a discount rate of 0%, apixaban dominates other strategies and with 3% discount rate, apixaban dominates other DOACs with an ICER of US\$36.79 relative to LMWH/VKA. In a different analysis of 3 months of therapy and for lifetime duration of the anticoagulation therapy, apixaban dominated other DOACs with an ICER relative to LMWH/VKA of US\$7379.66 and US\$174 614.23, respectively. However, with a 12-month therapy, apixaban dominated all other treatments.

Two studies reported the annual total medical cost avoidance as the primary measure.^[@bibr28-1076029619849103],[@bibr30-1076029619849103]^ Amin et al reported the annual total medical cost avoidance associated with DOAC use compared to placebo as US\$2794, US\$2948, US\$4249, and US\$4244 ppy for patients with VTE treated with dabigatran, rivaroxaban, apixaban 2.5 mg, and apixaban 5 mg, respectively, with the highest cost avoidance associated with apixaban 2.5 mg followed by apixaban 5 mg. A similar trend was also observed in a different study of theirs, where they reported annual total medical cost avoidance for VTE treatment with DOACs versus warfarin ppy as follows: US\$572, US\$2971, US\$4440, and US\$1957 with dabigatran, rivaroxaban, apixaban, and edoxaban, respectively.

Reporting the total medical cost differences as the outcome measure, in a third study of theirs, Amin et al reported that the use of DOACs in comparison to standard therapy was associated with overall medical cost differences of US\$146, US\$482, US\$918, and US\$344 for patient with VTE treated with dabigatran, rivaroxaban, apixaban, and edoxaban, respectively, with the highest cost differences associated with apixaban. When treatment duration was normalized, the annual total medical cost differences were US\$153, US\$454, US\$1108, and US\$261 for a patient with VTE treated with dabigatran, rivaroxaban, apixaban, and edoxaban, respectively, also with the highest cost differences associated with apixaban. [Table 3](#table3-1076029619849103){ref-type="table"} summarizes the time horizon, event of interest, comparators, outcome measures, and results of the cost-effectiveness analysis conducted in each article.

###### 

General View of the Model Structure and Events Used in the Included Articles.

![](10.1177_1076029619849103-table3)

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author                                       Time Horizon                              Event of Interest                                                                                               Comparators                                    Outcome Measure                         Results
  -------------------------------------------- ----------------------------------------- --------------------------------------------------------------------------------------------------------------- ---------------------------------------------- --------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------
  Al Saleh et al^[@bibr29-1076029619849103]^   Each cycle = 6 m\                         Recurrent DVT and PE and major bleeding                                                                         Dabigatran, rivaroxaban, apixaban, warfarin    ICER (Cost/QALY)                        Apixaban dominates other DOACs in 3, 6, aand 12 months and lifetime treatment duration
                                               Follow-up = 6 m, 12 m\                                                                                                                                                                                                                           
                                               Life-time                                                                                                                                                                                                                                        

  Amin, et.al^[@bibr30-1076029619849103]^      1 year                                    Recurrent VTE, major bleeding and CRNMB                                                                         Dabigatran, rivaroxaban, apixaban (2.5-5 mg)   Annual total medical cost avoidance     Apixaban 2.5 mg dominates other DOACs with US\$4249 cost avoidance compared to placebo

  Amin, et.al^[@bibr31-1076029619849103]^      1 year                                    Recurrent VTE, major bleeding, CRNMB and other minor bleeding                                                   Dabigatran, rivaroxaban, apixaban, edoxaban    Annual total medical cost differences   Apixaban dominates other DOACs with US\$918 cost difference compared to standard therapy

  Amin, et.al^[@bibr28-1076029619849103]^      1 year                                    Recurrent VTE and major bleeding                                                                                Dabigatran, rivaroxaban, apixaban, edoxaban    Annual total medical cost avoidances    Apixaban dominates other DOACs with cost avoidance of US\$2971 per patient year (ppy), compared to warfarin

  Jurgin et al^[@bibr26-1076029619849103]^     Each cycle = N/A\                         Recurrent VTE, MCRBE, CTEPH, and PTS                                                                            Dabigatran, rivaroxaban                        ICER (Cost/QALY)                        Dabigatran dominates rivaroxaban in all treatment settings
                                               Follow-up= 3 m, 6 m, 12 m and Life-time                                                                                                                                                                                                          

  Lanitis, et.al^[@bibr32-1076029619849103]^   Each cycle = 3 m\                         Recurrent VTE, major bleeding, CTEPH, CRNM, Death                                                               Dabigatran, rivaroxaban, apixaban, warfarin    ICER (Cost/QALY)                        Apixaban dominates rivaroxaban and LMWH/dabigatran in 6 months treatment duration and with ICER of US\$2520 relative to LMWH/VKA
                                               Follow-up = 3 m, 6 m, 12 m\                                                                                                                                                                                                                      
                                               Life-time                                                                                                                                                                                                                                        

  Quon et al^[@bibr27-1076029619849103]^       Cycle = 3 m\                              Recurrent PE and DVT, IC, non-IC major bleed, CRNM, treatment discontinuation, CTEPH, PTS, death, or no event   Dabigatran, rivaroxaban, apixaban, warfarin    ICER (Cost/QALY)\                       Apixaban dominates dabigatran, rivaroxaban with treatment duration up to 18 months and with ICER of US\$4827.78 relative to enoxaparin/VKA
                                               Follow-up= 3 m, 6 m, 12 m\                                                                                                                                                                                                                       
                                               Life-time                                                                                                                                                                                                                                        
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: CRNMB, clinically relevant non-major bleeding; CTEPH, chronic thromboembolic pulmonary hypertension; DOAC, Direct oral anticoagulants; DVT, deep venous thrombosis; IC, intracranial bleed; ICER, incremental cost-effectiveness ratio; MCRBE, major and clinically relevant bleeding event; PE, pulmonary embolism; PTS, post thromboembolic syndrome; QALY, quality-adjusted life-years; VTE, venous thromboembolism.

All studies performed probabilistic sensitivity analysis to ensure the robustness of their results. Jurgin et al reported that at £20 000 willingness to pay threshold (WTP), dabigatran therapy compared to 3-, 6-, and 12-month therapy of rivaroxaban had 61% and 88% probability of being good value for money in the treatment and extended anticoagulation of VTE, respectively, and 62% and 62% probability in DVT and PE, respectively. Furthermore, Lanitis et al reported that apixaban was also a dominant choice in 87% of the trials compared to rivaroxaban and in 98% of the trials compared to LMWH/dabigatran. Furthermore, in comparison to LMWH/VKA, apixaban was found to be the cost-effective choice in 100% of trials with an ICER of \< £20 000 per QALY. Moreover, Quon et al reported that at WTP of US\$5000 per QALY, apixaban had the highest probability of being cost-effective compared to dabigatran, rivaroxaban, and warfarin. At WTP of US\$10 000 and US\$50 000 for each additional QALY, apixaban had 93.5% and 97.7% probability of being the most cost-effective choice compared to other treatments. Amin et al reported both univariate and multivariate sensitivity analyses in all of their 3 studies. The results were also in favor of the original results with apixaban being associated with the highest cost avoidance and differences compared to dabigatran, rivaroxaban, and edoxaban.

Quality Assessment Results {#section15-1076029619849103}
--------------------------

The majority of studies were fair in quality, with none of the studies performing poorly. [Table 4](#table4-1076029619849103){ref-type="table"} represents the results of the quality assessment of the included articles.

###### 

Quality Assessment, QHES Tool.

![](10.1177_1076029619849103-table4)

  -----------------------------------------------------------------------------------------------------------
  Author                                         Score   Overall Assessment   Grading Criteria
  ---------------------------------------------- ------- -------------------- -------------------------------
  Al Saleh et al^[@bibr29-1076029619849103]^     82      Good Quality         Good Quality = 76-100 points\
                                                                              Fair Quality = 51-75 points\
                                                                              Poor Quality = 0-50 points\

  Amin et al^[@bibr30-1076029619849103]^         74      Fair Quality         

  Amin et al^[@bibr31-1076029619849103]^         71      Fair Quality         

  Amin et al(2015)^[@bibr28-1076029619849103]^   71      Fair Quality         

  Jurgin et al^[@bibr26-1076029619849103]^       89      Good Quality         

  Lanitis et al^[@bibr32-1076029619849103]^      88      Good Quality         

  Quon et.al^[@bibr27-1076029619849103]^         71      Good Quality         
  -----------------------------------------------------------------------------------------------------------

Discussion {#section16-1076029619849103}
==========

To our best knowledge, this is the first systematic review that summarizes cost-effectiveness studies comparing among DOACs in VTE, either directly or indirectly. There is lack of standardization on how systematic reviews of cost-effectiveness studies are to be conducted, and the current study achieves its objectives of comparatively summarizing the cost-effectiveness evaluations among DOACs for the purpose of health-care providers and decision makers in practices, including formulary decisions. It seems that the higher cost of DOACs was dominated by the value of their advantages of the minimized need for monitoring and the superior efficacy and safety profiles.

In relation to the results of efficacy end points, as seen in [Table 2](#table2-1076029619849103){ref-type="table"}, the majority of the studies (n = 5) concluded that apixaban was associated with the least number of clinical events in terms of recurrent VTE, compared to the other DOACs. Amin et al, however, reported that edoxaban was superior to apixaban in terms of the reduced recurrent VTE rate in the general population, with both showing superiorities in efficacy over the dabigatran and rivaroxaban. In the study by Quon et al, only investigating dabigatran and rivaroxaban, the latter was associated with superior efficacy compared to dabigatran. However, in all other included studies (n = 6), dabigatran had superior efficacy over rivaroxaban. In summary, edoxaban appears to be second to apixaban in efficacy, followed by dabigatran and then rivaroxaban. In relation to the efficacy against initial treatment and extended treatment of VTE, apixaban was demonstrated in this review to be the most efficacious, with a superior safety and efficacy profile, compared to other DOACs. These results come in line with previous studies evaluating the safety and efficacy of DOACs in different disease conditions.^[@bibr42-1076029619849103][@bibr43-1076029619849103]--[@bibr44-1076029619849103]^ Important to note is that results have to be interpreted cautiously giving that all comparative data are not based on head-to-head study sources and were all performed using clinical events reported in the literature. These events were extracted from studies that compared DOACs to the gold standard warfarin/LMWH. And to the best of our knowledge, there are no real-world head-to-head data in the VTE treatment/prophylaxis that compares DOACs in terms of effectiveness and/or safety.

Results of the cost-effectiveness analyses are based on studies from 3 different countries (United States, United Kingdom, and Canada), and they differ in the used economic model, study perspective (ie, the adopted viewpoint of the analysis regarding the type of included costs and effects; eg, society, payer, provider, and patient), comparators, acquisition costs, willingness-to-pay threshold, and presentation of results as well as the financial year of results. The variability in such important methodological aspects of studies makes the generation of cumulative quantitative evidence or summative cost values nonfeasible for DAOCs. Descriptive study results, nevertheless, and based on the currently available evidence, show that apixaban was the most cost-effective (dominant) option in terms of annual total medical cost avoidance, savings ppy and cost/QALY. In terms of VTE initial treatment, apixaban showed favorable prevention of VTE recurrence and reduction in bleeding events after 6 months of treatment, at a lower cost. The major and CRNM bleeding events were also lower with apixaban, compared to other DOACs, resulting in apixaban being a more cost-effective treatment option compared with other alternatives, including dabigatran and rivaroxaban. Rivaroxaban was inferior to apixaban but superior (cost-effective) over edoxaban and dabigatran. Edoxaban was inferior to both apixaban and rivaroxaban according to Amin et al, but it was superior to dabigatran in terms of annual total medical cost differences and avoidance per patient-year. Dabigatran was dominated in almost all cost-effectiveness studies, except in that by Jurgin et al, where it dominates rivaroxaban in terms of cost/QALY.

More importantly, results in this review are consistent with other reports in the literature, including systematic reviews, cost-effectiveness analyses and meta-analyses that also compared the cost-effectiveness among DOACs, and for stroke prevention in patients with atrial fibrillation.^[@bibr11-1076029619849103],[@bibr12-1076029619849103],[@bibr14-1076029619849103][@bibr15-1076029619849103]--[@bibr16-1076029619849103]^ An additional example of consistent results is a Monte-Carlo cost-effectiveness simulation of rivaroxaban against apixaban, where the former had the lowest cost compared to other DOACs, while the latter had the highest QALYs and was considered the most cost-effective.^[@bibr45-1076029619849103]^

This review includes several limitations. First, while the search strategy did include gray literature, this did not include nonpublished articles, which could have been of relevance. Also, the search was language restricted, where relevant articles could have been missed. Resources to translate non-English articles, however, are not available to authors. Additional articles could have been identified in the literature with the use of additional search engines. Here, nonetheless, it is noted that the PubMed and Embase databases cover almost 80% of the literature, and with the utilization of EconLit as well, the authors believe to have covered a representative sample of literature.^[@bibr46-1076029619849103]^ Additional articles could have also been found with other key search terms and/or new combinations of them. Here, of relevance, it is important to note that we included "atrial fibrillation" and "stroke" in the search terms, in case of having studies looking at VTE as a secondary underlying indication to the stroke and atrial fibrillation. This would help ensure the comprehensiveness of our search and reduce the possibility of missing any potential articles. Moreover, 6 of the included studies in this review were industry funded. A final limitation in the study is that the quality of journals and their editorial requirements were not weighed into the quality assessment.

Conclusion {#section17-1076029619849103}
==========

Apixaban dominates other DOACs for the prevention and treatment of VTE. In VTE extended treatment, apixaban was associated with the highest cost avoidance mainly due to the reduced rates of recurrent VTE and major bleeding compared to other DOACs. The cost-effectiveness of apixaban is followed by that of rivaroxaban, edoxaban, and then dabigatran.

Recommendation {#section18-1076029619849103}
==============

All economic studies in this review were not based on head-to-head clinical sources of data. They were based on the data obtained from the phase 3 clinical trials for each DOAC, when compared against warfarin. Thus, future head-to-head clinical studies among DOACs are recommended.
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